Objectives: The objectives of this study were to compare thromboelastography platelet mapping (TEG PM) with impedance aggregometry (Multiplate, MP) in a single trauma population and relate their results clinically.
Platelet function in trauma patients is clinically relevant because it is a vital component of haemostatic potential. Clinical measures of platelet function in cardiovascular and hepatic surgery are well established; however, investigation regarding its use in trauma is limited (Jacoby et al., 2001) . Light transmission aggregometry (LTA) has classically been used to determine platelet function associated with inherited or acquired bleeding disorders. However, the use of this technique is limited at the point of care because it requires significant sample processing (Ramsey et al., 2016) .
Recently, other point-of-care platelet function devices have been introduced to measure platelet function in trauma patients. Initial studies that employ these devices have revealed significant reductions in platelet function that persist for days following traumatic injury. These reductions in platelet function are observed in the presence of a normal platelet count, vary with the type of injury and may occur even with minor injuries (Sirajuddin et al., 2016) . Platelet dysfunction in patients with traumatic injury has been associated with a decrease in haemostatic potential (Wohlauer et al., 2012) , increased need for blood product transfusion (Stein et al., 2017) and poor outcomes. The point-of-care methods employed to determine platelet function are viscoelastometry and impedance aggregometry. Both methods have been validated and approved by the US Food and Drug Administration based on the comparison with LTA by demonstrating close agreement with LTA.
The use of point-of-care platelet function tests to direct haemostatic therapy after trauma is emerging. However, no study directly compares the two available devices to assess their concordance. There is a significant lack of knowledge regarding whether these two approaches to platelet function testing give similar results or can be used interchangeably. In this study, we compare thromboelastography platelet mapping (TEG PM) and impedance aggregometry (Multiplate) to determine the degree of agreement between these two point-of-care platelet function devices.
METHODS

Human subjects
This prospective observational study was conducted at the Memorial Hermann Hospital within the Texas Medical Center, Houston, Texas, USA. Prior to the study, approval was obtained from the Institutional Review Board (HSC-GEN-12-0059). Patients meeting the highest level of trauma team activation were included in the study from June 2016 to September 2016. If the patients were younger than 16 years, pregnant, prisoners, enrolled in other studies or declined to give the informed consent, they were excluded from the study. The presence of antiplatelet medications or NSAIDS was not an exclusion criterion for this study. The patients from whom we could not obtain an admission blood draw were excluded from the study. Informed consent was obtained from the patient or a legally authorised representative within 72 h of admission. A waiver of the informed consent was obtained for those patients discharged or who died within 24 h. In the remaining cases in which the informed consent could not be obtained, the patients were excluded from the study and their blood samples were destroyed.
Blood samples from trauma subjects were drawn with the initial sample approximately 10 min after arrival to the hospital. 20 mL of blood was drawn through venipuncture into Vacutainer tubes containing 3·2% of citrate or heparin and inverted to assure proper anticoagulation. Platelet function was assessed using TEG PM and Multiplate (MP) within one hour after sample collection. Samples obtained from different subjects were also run in single devices in duplicate. Vital signs, injury data, Injury Severity Score, laboratory data and demographic variables were also recorded. After review of medications, no subjects in this study were noted to take antiplatelet medications or NSAIDS.
Thromboelastography
All TEG PM assays were run on Thromboelastograph 5000 (Haemoscope Corporation, Niles, IL, USA) by trained on-call research personnel. TEG PM can detect various antiplatelet drugs including aspirin and clopidogrel by measuring independently the contribution of adenosine diphosphate (ADP) and thromboxane (TxA2) platelet activation pathways to clot formation. Maximum amplitude (MA), the primary assay metric, is a measurement of clot stiffness associated with the contribution of fibrin and platelets. To measure the percentage activation of either platelet pathway, four channels of TEG tracings are required -(i) kaolin-induced TEG to measure the maximum clot formation in response to thrombin (MA THROMBIN ), (ii) reptilase and activated FXIII (activator F) to polymerise and cross-link fibrin without platelet activation to measure the isolated fibrin component (MA FIBRIN ) and activator F plus either (iii) ADP (MA ADP )-or (iv) arachidonic acid (AA) (MA AA )-induced TEG to measure the pathway-dependent contribution of platelets to clot formation (Bochsen et al., 2007) . MA from each channel is recorded, and the percentage of platelet activation for a given platelet activation pathway is calculated as follows:
For MA THROMBIN , 340 μL of the citrated blood mixed with kaolin is added to 20 μL of 0·2 M CaCl 2 . For MA FIBRIN , 360 μL of the heparinised blood is added to 10 μL of activator F. For MA ADP or MA AA , 360 μL of the heparinised blood is added to 10 μL of activator F plus either 10 μL of the ADP or AA agonist. The addition of the ADP or AA agonist to activator F reflects the contribution of the P2Y1 and P2Y12 receptors or COX-1 receptor. Single assays were run for all enrolled patients, and single device duplicates were run for selected patients. It takes approximately 1 h and 15 min to complete each TEG PM assay.
Impedance aggregometry using MP
Platelet aggregation was measured simultaneously using impedance aggregometry in whole blood. Assays were performed using MP (Verum Diagnostica GmbH, Munich, Germany). This method measures platelet function by agonist-induced platelet aggregation onto two electrodes submerged in a stirred blood sample. The resulting increased electrical resistance (i.e. impedance) between the electrodes from platelet adherence is measured as an indicator of the ability of platelets to adhere to surfaces and to each other. Four different agonists were used -ADP (20 μL 6·5 μM, receptor pathway P2Y12), thrombin-receptor activating peptide-6 (thrombin receptor-activating pathway [TRAP] , 20 μL 32 μM, PAR receptor pathway), AA (20 μL 0·5 mm, COX-1 pathway) and ristocetin (RISTO, 50 μL 0·8 mg mL −1 , GPIb-IX-V receptor pathway). In this study, only ADP and AA agonists are presented because TEG PM only has the corresponding ADP and AA channels. To perform this assay, 300 μL of the whole blood is added to the electrode cartridge and diluted in the ratio of 1 : 1 with sodium chloride or calcium chloride. A magnetic stir bar assures the rapid mixing of blood and agonist throughout the measurement, and the electrode impedance is measured continuously for 6 min. The values are recorded as area under the impedance curve (AUC). Normal ranges stated by the manufacturer for MP ADP test is 57-113 AUC and the AA test is 71-115. Single assays were run for all enrolled patients, and single device duplicates were run for selected patients. It takes 10 min to complete each MP assay.
Replicate subjects
Forty different subjects, 20 for each device, were recruited under the above protocol to run the replicate assays.
Fig. 1.
Pearson's correlation for duplicates in MP using the ADP and AA channels. Each point represents the assay value in test 1 (x-axis) and test 2 (y-axis), respectively. P value for all correlations is <0.0001.
Fig. 2.
Pearson's correlation for duplicates in TEG PM using the ADP and AA channels. Each point represents the assay value in test 1 (x-axis) and test 2 (y-axis), respectively. P value for all correlations is <0.0001.
Trauma subjects
Fifty-two subjects different from those for device replicates were recruited under the above protocol for testing with both TEG PM and MP devices.
STATISTICS
The statistical analysis was carried out using Stata 14.2 (College Station, TX, USA). The Shapiro-Wilk analysis was used to determine the normality of continuous data. For normally distributed data, Pearson's correlation was used to correlate the device results; otherwise, Spearman's rank correlation coefficient was used. The other data are expressed as the mean and standard deviation if normally distributed; otherwise, they are expressed as the median and interquartile range (IQR). To determine the differences between clinical outcomes, Student's t-test was used for normally distributed data and Mann-Whitney U-test was used for significantly skewed data. For all analyses, the statistical significance was set to P < 0·05.
RESULTS
Repeatability for TEG platelet mapping and MP
For each device, 20 patients were enrolled for replicate testing. Replicates in MP were concordant (Fig. 1) . The agreement between test 1 and test 2 was higher in the AA channel compared to the ADP channel. The mean (±SD) AUC for the ADP replicates was 66 (±22) and that for the AA replicates was 53 (±23).
Replicates in TEG PM were also concordant (Fig. 2) . Median and inter-quartile range (IQR) percentage platelet activation for the ADP replicates was 37% (9%, 57%) and AA replicates was 76% (44%, 90%).
Comparison of TEG platelet mapping to MP
Fifty-two patients were enrolled, 78% of which were male. The mechanism of injury was blunt in 85% of patients, and the median Injury Severity Score (ISS) was 21·5 (10, 27), which was severe. The demographic data are presented in Table 1 . TEG PM correlated poorly with MP in the ADP channel and moderately in the AA channel (Fig. 3) . The median values for MP and TEG PM are given in Table 2 .
Clinical correlation of TEG platelet mapping and impedance Aggregometry
Forty-eight percent of patients received blood products within the first 4 h after arrival to the hospital (packed red blood cells, plasma, platelets, or cryoprecipitate). The TEG PM values were significantly lower in patients receiving any blood products within the first 4 h after arrival to the hospital compared to those patients who did not for ADP (7% (1%, 35%) vs 54% (14%, 71%) platelet activation, Wilcoxon's P = 0·0073) and AA (73% (12%, 90%) vs 91% (80%, 96%) platelet activation, Wilcoxon's P = 0·0376). The mean (±SD) MP values showed no such differences in either the ADP channel [AUC = 74 (6) vs 74 (5), P = 0·478] or the AA channel [AUC = 56 (6) vs 63 (5),
In this cohort, the mortality rate was 17% (Table 1) . The MP values were significantly decreased in patients who died at any time during their hospital stay in the AA channel (AUC = 44 (7) vs 64 (4), P = 0·023) but not in the ADP channel (AUC = 70 (7) vs 77 (4), P = 0·23). No significant association with mortality was observed while using TEG PM in either the AA channel [60% (34%, 80%) vs 89% (74%, 94%) platelet activation, Wilcoxon's P = 0·350] or the ADP channel [13% (4%, 72%) vs 35% (8%, 64%) platelet activation, Wilcoxon's P = 0·863].
Base deficit (BD) ≥ 8, an indicator of haemorrhagic shock, was present in 21% of patients. The TEG PM values were significantly decreased in patients with BD of 8 or greater in the ADP channel (7% (1%, 21%) vs 37% (10%, 67%) platelet activation, Wilcoxon's P = 0·018) but not in the AA channel (71% (34%, 80%) vs 90% (74%, 96%) platelet activation, Wilcoxon's P = 0·0730). No significant difference in BD was observed while using MP in either the ADP channel [70 (30) vs 75 (28), P = 0·87] or the AA channel [50 (25) vs 62 (29), P = 0·68].
The median ISS in this population of trauma patients was 21·5 (10, 27). For patients with ISS ≥ 25, no significant difference in platelet dysfunction was observed while using either device compared to the less injured cohort.
DISCUSSION
In this study of platelet function in severely injured trauma patients, MP and TEG PM were compared using the ADP and AA channels. The devices correlate moderately in the AA channel and poorly in the ADP channel. Duplicate testing of each device showed that both assays are repeatable.
Device discordance in trauma patients may exist because each device offers fundamentally different measurements of platelet function. Platelet-platelet aggregation after activation is promoted by the increased surface membrane expression of the fibrinogen-binding integrin IIb 3 in addition to the conformational change in these integrins from a low-affinity state to a high-affinity state. MP measures this aspect of platelet function. Further platelet cytoskeletal rearrangement follows platelet aggregation however it is not measured by MP. (Torti et al., 2000) . On the contrary, full cytoskeletal activation and rearrangement is required to produce platelet-induced clot contraction, which is the process measured by TEG PM.
The inherent differences between platelet aggregation and cytoskeletal contraction are also highlighted by the different energetic processes required. Platelet aggregation, the primary signal in MP (Cardinal & Flower, 1980) , is accompanied by increased platelet energy consumption in the form of ATP. Increased energy demand during aggregation is compensated for by increased glycolytic flux, without requiring platelet mitochondria-derived oxidative phosphorylation (Ravi et al., 2015) . Platelet-induced clot contraction, measured by TEG PM, also requires energy in the form of ATP. However, unlike aggregation, platelet contraction is sensitive to changes in oxidative phosphorylation (Holmsen et al., 1979) . Also, platelet contraction in TEG PM occurs and is measured over the course of an hour, whereas aggregation in MP takes in 6 min to complete. This shows that TEG PM would be potentially more sensitive to metabolic derangement in traumatic injury because it relies more on continuous in vivo oxidative energy production rather than the short-term stored glycolytic energy used in aggregation (Verhoeven et al., 1986) . Finally, TEG PM is more reflective of the total energetic potential of platelets. In vitro testing has proven this concept. Verhoeven et al. measured the energy consumed during platelet aggregation and concluded that the increased energy consumption during aggregation does not change when the platelet actin-myosin contractile apparatus is inhibited by cytochalasin. Furthermore, aggregation was unaffected by cytochalasin (Verhoeven et al., 1986) . However, the elimination of the platelet contribution to clot strength in viscoelastic assays is commonly achieved by inhibiting the polymerisation of actin using cytochalasin (Schlimp et al., 2014) .Thus, platelet aggregation measured by MP and cellular contraction measured by TEG PM appear to be promoted by separate intracellular mechanical and energetic responses.
The in vitro testing environment and physics governing these two devices are also vastly different. In MP, citrated whole blood is added to a heated electrode cartridge with a rotating stir bar. After the addition of the whole blood, platelets initially form a monolayer over the silver-coated copper sensor wires. Platelets, leucocytes and trapped red blood cells adhere to the platelet monolayer in response to different agonists. This cellular aggregation increases the electrical resistance, or impedance, of the circuit that drives the device signal. TEG PM utilises citrated-recalcified blood in a heated pin-and-cup device measuring shear resistance as a clot adheres and coagulation progresses. The device signal depends on two key players -(i) fibrin and (ii) platelets. Fibrin formation marks the transition from liquid to gel and drives the initial forces defining clot initiation, or R time, in a TEG curve. Platelets also contribute significantly towards fibrin cross-linking through glycoprotein IIb/IIIa and clot stiffening through contraction promoted by the platelet actin-myosin contractile apparatus. Previous estimations show that platelets contribute 80% of the total clot strength, with fibrin contributing the remaining 20% (Harr et al., 2013) . This contribution is reflected primarily in the MA metric in a TEG curve and is especially important in the TEG PM assay. The shear on the assay sample in TEG is very low compared to MP, with the cup rotating no more than 5 ∘ for every 10 s compared to a stir bar rotating up to 1200 rpm. Assay metrics in TEG are determined by factors such as thrombin production, fibrin polymeriaation and platelet contraction. TEG PM attempts to isolate platelet function through the AA and ADP platelet activation pathways, and it records the data during all phases of platelet function from aggregation to contraction.
However, changes in fibrin polymerisation may still influence platelet-induced clot contraction in the assay and cannot be fully decoupled from the measurement. The cumulative effect of the physical device differences in TEG PM and MP is a potentially discordant expression of platelet function. Although these two independent tests of platelet function only correlate moderately in the AA channel, they individually detect platelet dysfunction of clinical importance. MP has been found to predict mortality at the onset of trauma. Solomon et al. reported significant increases in mortality related to platelet hypofunction in trauma patients as measured by ADP and TRAP agonist pathways (Solomon et al., 2011) . Kutcher et al. found that platelet responsiveness to AA and collagen agonists in MP was predictive of both early mortality and late mortality despite normal platelet count (Kutcher et al., 2012) . Similarly, in the present study, mortality was found to be associated with decreased platelet responsiveness in the AA channel on MP. However, although platelet dysfunction measured by TEG PM was not associated with mortality, it was associated with the clinical measures of physiologic derangement such as increased BD and increased blood transfusion requirement, reflecting more likely the local metabolic state of the blood.
In agreement with our findings, Wohlauer et al. revealed an association between significant decreases in the TEG PM ADP channel and both transfusion requirements within 6 h after arrival to the hospital and haemorrhagic shock as measured by BD > 8. Similarly in the present study, the TEG PM ADP and AA channels were significantly decreased in patients requiring blood product transfusion within 4 h after arrival and BD > 8. However, our study differs from both Wohlauer and others in that no association was found between ISS and platelet dysfunction in the ADP channel (Wohlauer et al., 2012; Sirajuddin et al., 2016) . Regardless, the agreement between these two studies suggests that TEG PM is a useful clinical adjunct in the early decision to administer blood products to trauma patients. TEG PM is potentially a superior indicator of haemorrhagic shock in trauma patients compared to MP.
TEG PM is also useful in traumatic brain injury (TBI). Nekludov et al. studied TEG PM in trauma patients and found that low platelet responsiveness to AA was predictive of bleeding complications in patients with concomitant TBI, and however, similar association did not exist in trauma patients without TBI (Nekludov et al., 2007) . Davis et al. in a study of patients with TBI found that the severity of TBI and mortality was associated with low platelet responsiveness to ADP (Davis et al., 2013) . The specificity of TEG PM for true platelet dysfunction in trauma is questioned, however, by Sirajuddin et al. where marked platelet inhibition was found in minimally injured trauma patients (mean ISS = 7) (Sirajuddin et al., 2016) .
An ideal test of platelet function in trauma patients would isolate a platelet response reflective of patient physiology and would have high relevance to clinical bleeding management. Measurement of platelet metabolism or function more specifically may help to fulfil these requirements. MP relies on glycolysis and is predictive of mortality; however, it may be limited in its ability to guide haemorrhage management. The present study and that by Wohlauer et al. demonstrate that TEG PM, which relies more on oxidative phosphorylation, correlates with the degree of haemorrhagic shock measured by BD and early transfusion requirements. This may make TEG PM a more useful point-of-care measurement capable of informing early treatment decisions such as transfusion of platelet concentrates. However, TEG PM extrapolates the platelet contraction signal by subtracting the signal from fibrin formation. Thus, it is not a direct measure of platelet contraction. In the future, devices that could isolate and measure platelet contraction directly, such as those developed by Myers et al., 2017 and Feghhi et al., 2016 , could potentially remove the confounding influence of fibrin when seeking an ideal test of platelet contractile function.
Small sample size is one of the limitations of this study. Although the present study was sufficiently powered, similar studies by Sirajuddin and Solomon included hundreds of patients. Additionally, measurements of platelet glycolytic and mitochondrial function run simultaneously with the platelet function devices would have added significantly to this study. These data would allow the correlation between clinically defined platelet function and platelet bioenergetics and broaden the understanding of platelet dysfunction in trauma patients.
In summary, it is shown that platelet function measured by TEG PM and Multiplate in trauma patients correlates poorly with each other in the ADP channel and moderately in the AA channel. A potential reason for this is that each signal is governed by different metabolic pathways and each device measures different platelet responses to activation. However, both devices individually are repeatable as the duplicate variation in a single device is low. Also, clinical associations in this population of severely injured trauma patients were similar to previously published findings in both devices, except that there is no association with indices of injury severity in either device.
